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Abstract: 
Purpose 
Pain, depression, distress, fatigue, and sleep disturbance are common symptoms in oncology 
patients, but little data are available that examine the trajectories of these symptoms during 
chemotherapy (CTX). The purposes of this study were to examine the trajectories of these 
symptoms during the first six cycles of CTX and to determine whether individual characteristics 
predicted the trajectories of these symptoms. 
Methods 
Oncology outpatients (n = 118) with newly diagnosed lung cancer, colorectal cancer, or 
lymphoma rated symptoms using an electronic patient care monitor system. Pain, fatigue, and 
sleep disturbance were rated on 0–10 numeric rating scales; depression and distress were 
evaluated using scales converted to normalized T scores. Latent growth curve analyses (LGCA) 
examined for intra- and inter-individual differences in the trajectories of these five symptoms 
during the six cycles of CTX. 
Results 
Symptoms were present at the initiation of CTX (p < 0.0001) for all symptoms (p < 0.05). 
Distress (p = 0.03) and pain (p = 0.02) intensity decreased significantly over the six cycles of 
CTX. Advanced disease and a higher number of comorbidities predicted higher fatigue at 
baseline (p = 0.02 and 0.01 respectively). A diagnosis of lung cancer predicted an increasing 
intensity of fatigue during CTX (p = 0.04). Concurrent radiation therapy predicted more intense 
pain over time (p = 0.03). 
Conclusions 
While symptom trajectories were highly variable in patients undergoing initial CTX, the majority 
of the symptom intensity scores decreased over time. However, patients with lung cancer, those 
with a higher number of comorbidities, and those with advanced disease experienced more 
intense fatigue and sleep disturbance over time. 
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Article: 
Introduction 
While advances in early detection and treatment of cancer have led to increased survival rates, 
strides in symptom management have not kept pace (Patrick et al., 2003). Patients continue to 
experience an array of cancer and treatment-related symptoms that have deleterious effects on 
quality of life (QOL). Pain, depression, and fatigue are three of the most common symptoms 
associated with cancer and its treatment (Patrick et al., 2003). Sleep disturbances are prevalent 
and often coexist with pain, depression, and fatigue (Berger et al., 2005). In addition, distress, 
defined as the unpleasant experience of coping with cancer and its physical symptoms (NCCN., 
1999 and Redeker et al., 2000), can co-occur with these symptoms. These symptoms can exist 
throughout the cancer trajectory and be associated with the disease itself, cancer treatment, or 
comorbidities. 
 
Chemotherapy (CTX) is a mainstay of cancer treatment, and most patients will receive 
chemotherapy at some time during the cancer trajectory. For many, this occurs shortly after 
diagnosis as part of the initial cancer treatment (Oncology Nursing Society, 2009). A wide range 
of side effects occurs in conjunction with chemotherapy including pain, depression, fatigue, 
sleep disturbance, and distress (Honea et al., 2006). Unfortunately, little is known about the 
symptom experience over time during chemotherapy. Rather, most symptom research uses cross-
sectional designs and measures symptom prevalence at a single point in time. The limited studies 
that examine changes in symptom severity over time are discussed below. 
 
Symptom trajectories during CTX administration have received some attention, but the majority 
of these studies focused on changes in fatigue and/or sleep disturbance (Berger and 
Higginbotham, 2000, Braud et al., 2003, Molassiotis and Chan, 2001, Richardson et al., 1998 
and Schwartz et al., 2000). Peaks in fatigue were noted immediately after CTX administration 
(Berger and Higginbotham, 2000 and Schwartz, 2000), two to three days following CTX (Berger 
and Higginbotham, 2000, Molassiotis and Chan, 2001 and Schwartz et al., 2000), at neutrophil 
nadir (Richardson et al., 1998), and with bolus CTX regimens (Richardson et al., 1998). While 
some studies suggest that fatigue and sleep disturbances may increase over the course of CTX 
(Berger and Higginbotham, 2000, Danaher et al., 2006, Reyes-Gibby et al., 2007 and Schwartz et 
al., 2000), inter-individual differences may occur (Berger and Higginbotham, 2000). No studies 
were found that examined trajectories of pain, depression, and distress during chemotherapy, 
even though these symptoms often co-occur with fatigue and sleep disturbance. 
 
In addition, no studies have examined the predictors of symptom trajectories during CTX which 
would reveal inter-individual differences in symptoms over time. Only one study was found that 
identified the predictors of depression one year after cancer diagnosis in patients with breast, 
colon, lung, and prostate cancer. Predictors of depression were higher stage of disease, being 
female, greater number of comorbidities, and less education. However, it is unknown whether 
these patients underwent CTX (Stommel et al., 2004). 
 
Effective approaches to symptom management are dependent on an understanding of inter-
individual differences in the trajectories of patients’ symptoms. A National Institutes of Health 
(NIH) State-of-the-Science Conference convened to discuss the importance of fatigue, pain, and 
depression related to cancer and its treatment. The panel went on to say that repeated 
assessments of these symptoms should occur across the cancer and treatment trajectories, as it is 
not known if symptoms resolve, persist, or exacerbate over time. Without this knowledge, high 
risk groups cannot be identified and individualized treatments cannot be explored. The panel 
recommended additional research that examines the occurrence and treatment of these 
symptoms; specifically, longitudinal studies are needed that examine the severity and duration of 
these symptoms over time (Patrick et al., 2003). 
 
A modified version of the Symptoms Experience Model (Armstrong, 2003 and Brant et al., 
2010) served as the theoretical framework for this study. The model takes into account the global 
experience of cancer-related symptoms. Antecedents including individual characteristics (age, 
gender, education, race, religion, marital status) and disease characteristics (type of cancer, stage 
of disease, type of treatment, comorbidities) provide input into the symptom experience, that are 
individually defined by the patient. The modified model accounts for the dynamic nature of 
symptoms that evolve over time, due to symptom interaction of antecedent factors that contribute 
to the dynamic (changing) nature of the symptom experience. Finally, the modified model can be 
used to answer questions about the onset and rate of change in symptoms over time or how 
symptom trajectories change over the course of an illness or in this case, the chemotherapy 
treatment trajectory (Brant et al., 2010). These types of questions require longitudinal research 
designs (Barsevick et al., 2006). 
 
Overall, little is known about inter-individual differences in the trajectories of the majority of 
symptoms associated with cancer and cancer treatment. In addition, studies of predictors of 
symptom trajectories that could identify high risk patients are virtually nonexistent. 
Understanding more about the symptom experience during CTX could lead to the development 
of risk assessment tools and tailored interventions for patients whose physical and/or 
psychological symptoms persist. 
 
Therefore, in this study, latent growth curve analyses (LGCA) were used to examine trajectories 
in the severity of pain, fatigue, depression, distress, and sleep disturbance during the first six 
cycles of CTX in a sample of outpatients with lymphoma, colorectal, or lung cancer. The specific 
purposes of this study were: 1) to examine the trajectories of pain, fatigue, depression, distress, 
and sleep disturbance during the first six cycles of CTX and 2) determine whether individual 
characteristics (e.g. age, gender, co-morbidities, race/ethnicity type of cancer) predicted each of 
the symptom trajectories. 
 
Methods 
Patients 
The sample consisted of 118 patients with lung cancer (n = 55), colorectal cancer (n = 31), or 
lymphoma (n = 32) who had received CTX at the Hematology-Oncology Centers of the Northern 
Rockies (HOCNR) outpatient clinic in south central Montana from June 2004 to April 2007. 
These particular diagnoses were chosen as: 1) the malignancies represent both genders (an 
antecedent variable in this study) 2) the malignancies are some of the most common cancers 
treated at oncology clinics, and 3) so little is known about changes in the symptom experiences 
of these patients. In addition, these three diagnoses were selected to obtain an adequate sample 
size. Patients were included if they had a new cancer diagnosis; were to undergo an initial course 
of CTX; and had at least three symptom measures recorded in an electronic database over their 
first six cycles of CTX, each recorded on day one of the cycle. Patients who underwent CTX for 
recurrence were excluded. The study was approved by the Inter-institutional review board of 
Billings, Montana. 
 
Power analysis 
Analysis of variance (ANOVA) and repeated measures analysis of variance (RM-ANOVA) are 
traditional analytical strategies for measuring change over time. These two methods evaluate 
group change, but they lack the ability to study individual change over time according to group. 
Latent growth curve analyses have the ability to address these individual changes over time and 
identify predictor variables that indicate which individuals are most likely to respond in a 
particular manner over time. In this study, it can identify which individuals are most likely to 
develop specific symptom patterns over time (Muthen, 2003). The chi-square test for model fit is 
the most direct measure of power for LGCA, however estimation theory for SEM-type models is 
asymptotic (based on large samples). While small samples can be used, parameter estimates may 
be biased, and caution should be used in interpretation of results (Bollen and Curran, 2006). 
 
Data collection tool 
Symptoms were assessed using the Patient Care Monitor (PCM), a handheld, electronic tool that 
recorded information on patients’ symptoms in the waiting room prior to each outpatient visit. 
The PCM is a part of Supportive Oncology Services (SOS), an initiative to improve assessment, 
documentation, and management of cancer symptoms in adult outpatients (Maxon, 2005). 
HOCNR was an alpha site for the initiative and began using the PCM in June 2004. Nine self-
reported, demographic variables were entered into the PCM during the first outpatient visit: age, 
gender, type of cancer, stage of disease, number of comorbidities, marital status, education level, 
race, and religion. 
 
Patients entered symptom data into the PCM at each outpatient visit but not more frequently than 
once every two weeks. The PCM (1.0) contained a list of 38 symptoms. Only 5 of these 
symptoms were evaluated in this study. Only data entered on day one of each cycle was used in 
the analysis. 
 
Each symptom was rated on a 0–10 scale (0 = not a problem, 1 to 3 = mild problem, 4 to 6 = 
moderate problem, 7 to 9 = severe problem, 10 = as bad as possible). Patients were asked to rate 
each symptom on a separate screen of an electronic tablet using the time frame of the past week, 
including today. Pain, fatigue, and sleep disturbance were measured using a single item for each. 
Depression and distress were measured using 7 and 4 item scales respectively. Normalized T 
scores (mean 50, SD 10) were automatically calculated from the depression and distress items to 
create a composite score for each symptom that ranged from 42.92 to 79.89 and 37.93 to 74.56, 
respectively. Original developers of the PCM computed the normalized T scores using data from 
a reference sample of a heterogeneous group of oncology patients in Memphis, Tennessee. The T 
scores were created so that any given patient could be compared to other patients being treated in 
an outpatient oncology clinic. 
 
The PCM has undergone extensive psychometric testing and evidence exists to support its 
validity and reliability (Fortner et al., 2003). Cronbach’s alpha for this sample for all five 
symptoms was 0.86. 
 
Data download and cleaning 
PCM records from 530 patients (4287 time points) with a diagnosis of lymphoma, colorectal 
cancer, or lung cancer were downloaded from the SOS main database to a SPSS file. The dates 
of data input spanned from June 2004 when the PCM was initiated at the clinic through April 
2007. The 530 patients were matched with paper and electronic records at HOCNR and reviewed 
by hand for eligibility. CTX cycle dates, not included in the PCM data, were inserted at each 
point of symptom measurement for the 118 eligible patients. Patients were excluded for the 
following reasons: did not meet inclusion criteria for diagnosis (n = 27), fewer than three data 
points during CTX (n = 73), treated for relapsed disease (n = 53), no CTX (n = 222), and 
unavailable CTX cycle data (n = 37). 
 
Data were cleaned and analyzed in SPSS to: 1) delete duplicate cases, 2) assess for missing data, 
3) reduce the data set to the eligible sample, 4) reduce the data set to reflect only the variables 
needed for this study, and 5) flip the data set from a person-period data set (vertical format where 
each patient visit was entered on a new row) to a person level data set (a standard horizontal 
format where each patient had multiple and time tagged visits listed on one row). Nomenclature 
was developed to distinguish each of the visits according to the course number, CTX cycle 
number, day number of each CTX cycle, and visits not associated with CTX administration. This 
approach was essential so that day one of each CTX cycle for each patient could be evaluated in 
the analysis. 
 
Descriptive analyses were completed in SPSS (version 12.0) for Windows for each symptom at 
each of the six time points to produce means and standard deviations (SD). Data were then 
exported in a piecemeal process (each individual symptom with predictors) to MPlus 5.0 to 
conduct LGCA. Because LGCA is an emerging analytic technique in nursing science, some 
details are provided below. 
 
Statistical analysis 
LGCA, implemented in MPlus (Muthen and Muthen, 1998–2007) was used to estimate and 
evaluate trajectories of symptom change over time and to identify predictor variables associated 
with the individual growth curve parameters. MPlus uses a structural equation model (SEM) 
framework for modeling symptom change over time. Symptom change over time is 
conceptualized as a latent trajectories or growth curves defined by coefficients of linear 
(intercept, slope) and quadratic polynomial functions and time for each patient (Fig. 1). These 
individual curve parameters are then used as outcomes in a conditional analysis used to assess 
the impact of covariates on the individual patient trajectories for each symptom (i.e. depression, 
distress, pain, fatigue, sleep disturbance) over six CTX cycles. Data were centered on day one of 
cycle one (i.e. day one cycle one) and set to zero in the analysis, representing the intercept of the 
growth curve for each patient. The linear rate of constant change (acceleration or deceleration) 
for each symptom over time is reflected in the slope, and the nonlinear rate of change is reflected 
in the quadratic parameter. A positive slope indicates an increase in symptom severity over time 
whereas a negative slope constitutes a decrease. For the quadratic growth trajectory, a positive 
term represents increasingly faster changes as time goes by and a concave trajectory, whereas a 
negative coefficient represents a rate of change that decreases faster as time goes by and 
produces a convex trajectory. 
Figure 1 has been omitted from this formatted document. 
Initially, unconditional models were estimated to select a functional form (linear or quadratic) for 
each symptom trajectory. Standard approaches to model evaluation were used (Bentler, 1990, 
Bentler and Bonett, 1980, Bentler and Yuan, 1999, Browne and Cudeck, 1993 and Hu and 
Bentler, 1999). Better model fit and power were indicated by a nonsignificant X2 value, a 
comparative fit index (CFI) > 0.90, a Tucker Lexis Index (TLI) > 0.95, and a root mean square 
error of approximation (RMSEA) of < 0.06 for a good fit and 0.60 to 0.80 for a fair fit. The 
standard root mean squared residual (SRMR) < 0.08 was also noted. 
 
Selection of a functional form for each symptom trajectory was evaluated to study the impact of 
covariates. Each of the ten demographic and clinical characteristics (i.e. age, gender, 
comorbidities, type of cancer, stage of disease, marital status, education, race, religion, 
concurrent CTX) was entered one by one into each of the five symptom models (for a total of 50 
conditional models) to test whether each of the characteristics could predict the growth 
parameters. Some characteristics were recoded as dichotomous variables: type of cancer coded 
as lung (coded as 2) or not (coded as 1), married/partnered or not, Caucasian or other, Christian 
religion or other, high school diploma or less versus more than high school, and concurrent 
radiation therapy or not. A nominal significance level of p < 0.05 was used to test parameter 
estimates in all models. 
 
Results 
Demographic and clinical characteristics 
Table 1 provides a summary of the demographic and clinical characteristics of the sample. The 
majority of patients were male (55.9%), married/partnered (64%), and white (91.5%) with a 
mean age of 63.27 (SD 12.45) years. Almost half of the sample had a diagnosis of lung cancer 
and 44.9% had Stage IV disease. The mean number of comorbidities was 2.5 (range 0–8). The 
most common comorbidities were hypertension (35.6%), cardiac problems (20.3%), gastric 
problems (18.6%), and chronic obstructive pulmonary disease (COPD) (13.6%). While most of 
the patients received CTX alone (72.9%), approximately 15% received concurrent radiation 
therapy. 
Table 1. Demographic and Clinical Characteristics of the Sample (n = 118). 
 No (%) 
Demographic characteristics 
Gender 
 Male 66 55.9 
 Female 52 44.1 
Age 
 24–40 6 5.1 
 41–55 22 18.6 
 56–65 29 24.6 
 65–74 43 36.4 
 75–84 18 15.3 
Marital Status 
 Single 9 7.6 
 Separated 2 1.7 
 No (%) 
 Divorced 14 11.9 
 Widowed 17 14.4 
 Partnered 76 64.4 
Race 
 Caucasian 108 91.5 
 Native American 5 4.2 
 Hispanic 3 2.5 
 Other 2 1.8 
Religion 
 Protestant 61 51.7 
 Catholic 29 24.6 
 Other 19 16.0 
 None 9 7.6 
 Clinical Characteristics 
Type of Cancer 
 Lung 55 46.6 
 Colorectal 31 26.3 
 Lymphoma 32 27.1 
Stage of Disease 
 I 6 5.1 
 II 25 21.2 
 No (%) 
 III 34 28.8 
 IV 53 44.9 
Comorbidities 
 0 4 3.4 
 1 31 26.3 
 2 37 31.3 
 3 25 21.2 
 4 10 8.5 
 >4 11 9.3 
Treatment 
 CTX Alone 86 72.9 
 Concurrent CTX and XRT 18 15.2 
 XRT following CTX 14 11.9 
CTX = Chemotherapy, XRT = Radiation Therapy. 
Symptom severity over six cycles of CTX 
The mean symptom severity scores, SDs, and number of patients for each of six time points are 
provided in Table 2. Distress scores were more intense than depression at time 1 (53.98 versus 
51.80) but both remained near the normalized mean of 50 at all time points. Fatigue had a higher 
mean severity score of 3.90 at time compared to pain (3.00) and sleep disturbance (2.63). 
Table 2. Symptom Severity Scores for Each Symptom Over Time. 
 Time 1 
 
Time 2 
 
Time 3 
 
Time 4 
 
Time 5 
 
Time 6 
 
 n = 107 
 
n = 95 
 
n = 94 
 
n = 82 
 
n = 63 
 
n = 54 
 
Symptom Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Depression 51.80 9.78 51.36 9.49 51.39 8.83 49.25 9.28 49.37 9.15 51.05 9.72 
Distress 53.98 11.15 51.71 9.59 49.35 9.68 47.95 9.94 46.91 10.10 48.43 11.10 
Pain 3.00 3.05 2.14 2.64 2.16 2.58 1.41 2.13 1.41 2.12 1.91 2.50 
Fatigue 3.90 2.62 3.49 2.57 3.81 2.50 3.43 2.52 3.22 2.69 3.44 2.51 
Sleep 
Disturbance 
2.63 2.77 2.34 2.66 2.19 2.45 2.09 2.47 1.90 2.33 1.58 2.21 
Note: Each time associated with Day 1 of the first 6 cycles of chemotherapy. Depression and 
Distress based on Normalized T-scores (Mean 50, SD 10); Pain, Fatigue, Sleep Disturbance 
scores range from 0 (not problem) to 10 (as bad as possible). 
Unconditional and conditional model fit 
Growth curve modeling was conducted for each symptom in MPlus (Muthen and Muthen, 1998–
2007), and unconditional models were estimated so that a functional form of change could be 
selected (linear or quadratic). Table 3 lists the fit statistics for each symptom. Linear models 
were justified for depression, distress, fatigue, and pain trajectories. For distress and pain, both 
linear and quadratic models showed a fair fit, but the TLI greater than one indicated a slight over 
fit for the quadratic model, thus the linear model was chosen. Quadratic change was a better 
characterization of the sleep disturbance trajectories. 
Table 3. Unconditional Model Fit Statistics for Each Symptom. 
Symptom n df X2 p CFI TLI RMSEA SRMR 
Depression 
 Linear 113 16 19.030 0.2671 0.989 0.989 0.041 0.092 
 Quadratic 113 12 17.209 0.1419 0.981 0.976 0.062 0.070 
Distress 
 Linear 113 16 18.154 0.3150 0.992 0.992 0.035 0.117 
 Quadratic 113 12 10.228 0.5960 1.000 1.008 0 0.074 
Symptom n df X2 p CFI TLI RMSEA SRMR 
Pain 
 Linear 118 16 27.617 0.0350 0.941 0.945 0.078 0.110 
 Quadratic 118 12 8.568 0.7393 1.000 1.022 0 0.055 
Fatigue 
 Linear 118 16 26.062 0.3150 0.930 0.935 0.073 0.091 
 Quadratic 118 12 18.847 0.5960 0.953 0.941 0.070 0.063 
Sleep Disturbance 
 Linear 118 16 28.363 0.0286 0.879 0.886 0.081 0.141 
 Quadratic 118 12 11.760 0.4652 1.000 1.003 0 0.064 
Note. CFI = comparative fit index, TLI = Tucker-Lewis index, RMSEA = root mean square error 
of approximation, SRMR = standardized root mean square residual. Model Fit based on desired 
fit statistics of X2 test, p > 0.05, CFI > 0.95, TLI > 0.95 (over fit > 1) , RMSEA < 0.06 (fair 0.06–
0.08); SRMR < 0.08. 
Unconditional models of symptom trajectories over time 
Fig. 2 shows “spaghetti plots” of observed trajectories for individuals using fatigue as an 
example. Fig. 2A is a plot of 20 patient trajectories used to demonstrate the high degree of 
variability in trajectories over time that is often seen in clinical settings. Fig. 2B represents a 
subset of 5 patient trajectories in which variable patterns can be more easily observed. Patterns 
are not completely discerned until data are modeled via LGCA. Growth curve estimates for the 
selected functional forms in the unconditional models are listed in Table 4. For all five 
symptoms, the mean for intercepts of the unconditional models were all significant (p < 0.0001) 
which indicates a significant difference from zero and the presence of all five symptoms at the 
initiation of CTX. A significant variance was found for each symptom’s intercept except for 
sleep disturbance (p = 0.64). This finding indicates a high degree of inter-individual variability in 
the severity of depression, distress, fatigue, and pain existed at the initiation of CTX and that 
potential predictors for these differences could be evaluated. 
Figure 2 has been omitted from this formatted document. 
Table 4. Estimates, Z-Scores, and p values for Each Symptom’s Unconditional Model. 
Symptom Estimate Z-score p Variance Z-score p 
Depression 
 Intercept 51.197 56.142 p < 0.0001∗ 49.516 4.138 p < 0.0001∗ 
 Slope −0.127 −0.693 p = 0.488 0.381 0.847 p = 0.0397 
Distress 
 Intercept 51.557 48.292 p < 0.0001 84.682 4.724 p < 0.0001 
 Slope −0.884 −3.869 p < 0.0001 1.530 2.174 p = 0.030 
Pain 
 Intercept 2.510 8.657 p < 0.0001 6.755 4.454 p < 0.0001 
 Slope −0.215 −3.039 p = 0.002 0.161 2.288 p = 0.022 
Fatigue 
 Intercept 3.805 14.302 p < 0.0001 3.592 2.906 p = 0.004 
 Slope −0.058 −0.783 p = 0.434 0.237 2.648 p = 0.008 
Sleep 
 Intercept 2.506 9.953 p < 0.0001 2.388 1.853 p = 0.064 
 Slope −0.122 −0.582 p = 0.560 1.033 1.231 p = 0.218 
 Quadratic −0.007 −0.174 p = 0.862 0.029 1.061 p = 0.289 
Note: Intercept is set to zero.*p < 0.05, **p < 0.0. 
The negative linear slopes for each of the symptoms indicated that on average, symptom severity 
scores decreased over time. However, the rate of change was significant only for distress (p = 
0.03) and pain (p = 0.002). Sleep disturbance had both a negative slope and a quadratic term, 
indicating a convex trajectory. However, neither the slope nor quadratic term was significant. 
The slope variances (random effects) were significant (p < 0.05) for distress, fatigue, and pain. 
This finding suggested that potential predictors could be evaluated to identify factors associated 
with individual differences in rates of change for each of these symptoms. 
 
Conditional models of symptom trajectories over time 
Conditional models demonstrated that some demographic and clinical characteristics were 
significant predictors of inter-individual differences in the intercept as well as the rate of change 
in symptom trajectories over six chemotherapy cycles. Table 5 includes a summary of the 
conditional model estimates. No predictors of initial levels of distress were found in the 
conditional models. The fatigue slope was predicted by a diagnosis of lung cancer; patients with 
lung cancer experienced an increase in fatigue during CTX. An expression of growth curve 
parameters with the unconditional curve and conditional curve for lung cancer and fatigue are 
modeled in Fig. 3. As shown, fatigue severity increased in patients with lung cancer while 
fatigue severity decreased over time in those diagnosed with colorectal cancer and lymphoma. In 
addition, patients with more advanced cancer (p < 0.05) and a higher number of comorbidities (p 
< 0.01) had higher fatigue severity scores at the initiation of CTX (intercept). An increase in pain 
severity over time (opposite of the unconditional model that showed a decrease over time) was 
predicted by concurrent radiation therapy (p < 0.05). 
Table 5. Significant Estimates, Standard Errors and p Values for Conditional Models. 
Condition Depression 
 
Distress 
 
Pain 
 
Fatigue 
 
Sleep Disturbance 
 
Estimate SE Estimate SE Estimate SE Estimate SE Estimate SE 
Cancer Type (Lung or not) 
 Intercept −3.16 1.62 −2.54 1.90 −0.37 0.52 −0.45 0.44 −0.56 0.51 
 Slope −0.48 0.36 −0.29 0.45 −0.11 0.14 −0.29∗ 0.14 0.21 0.44 
 Quadratic         −0.02 0.08 
Stage 
 Intercept 0.22 0.91 0.33 1.05 0.44 0.28 0.54∗ 0.24 0.39 0.27 
 Slope −0.17 0.21 −0.03 0.26 −0.12 0.08 −0.15 0.08 −0.32 0.23 
 Quadratic         0.05 0.04 
Co-morbidities 
 Intercept 0.03 0.55 −0.05 0.64 0.11 0.17 0.36∗∗ 0.14 −0.11 0.16 
 Slope 0.14 0.14 0.12 0.17 −0.06 0.05 −0.07 0.05 0.34∗ 0.14 
Condition Depression 
 
Distress 
 
Pain 
 
Fatigue 
 
Sleep Disturbance 
 
Estimate SE Estimate SE Estimate SE Estimate SE Estimate SE 
 Quadratic         −0.07∗∗ 0.03 
Race 
 Intercept 2.62 2.83 0.16 3.32 0.73 0.94 0.04 0.81 1.14 0.91 
 Slope −0.11 0.578 0.03 0.72 −0.20 0.23 −0.02 0.26 −1.66∗ 0.75 
 Quadratic         0.31∗ 0.14 
Concurrent XRT 
 Intercept −1.24 2.34 0.17 0.11 0.17 0.11 0.20 0.11 0.17 0.11 
 Slope 0.69 0.56 0.03 0.98 −0.43∗ 0.20 0.10 0.23 −0.59 0.63 
 Quadratic         0.15 0.13 
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. 
Figure 3 has been omitted from this formatted document. 
The quadratic conditional models for sleep disturbance revealed that comorbidities were a 
significant predictor of the linear and quadratic curvilinear trajectories. For each increase in the 
number of comorbidities (e.g., from 2 to 3), there was an increase in the linear slope of 0.34 (p < 
0.05) and a decrease in the quadratic term of −0.07 (p < 0.01). Therefore, patients with an 
increased number of comorbidities reported more difficulty sleeping over the six cycles of CTX 
but that this increase leveled off over time, indicated by the small negative quadratic term. 
Finally, race contributed to linear and quadratic terms for sleep disturbance; Non Caucasian 
patients reported higher levels of sleep disturbance over time than Caucasian patients (p < 0.05). 
 
Discussion 
This novel, clinical database study is the first to our knowledge to model trajectories of change 
over time in some of the most common symptoms (depression, distress, fatigue, pain, and sleep 
disturbance) reported by oncology patients during the first six cycles of CTX. In addition, 
findings from this study suggest that some patients may experience more intense and unrelieved 
symptoms over the CTX trajectory. 
 
Notably, a significant amount of depression, distress, fatigue, pain, and sleep disturbance were 
present at the initiation of CTX (p < 0.0001). This finding suggests that some patients begin 
CTX with physical and psychological morbidity and may require supportive care early in the 
disease/treatment trajectory. For all five symptoms, average severity scores decreased over the 
six cycles of CTX. This finding is consistent with a limited number of studies on distress 
(anxiety) (Braud et al., 2003), fatigue and sleep disturbance ( Gift et al., 2003 and Reyes-Gibby 
et al., 2007), and depression (Stommel et al., 2004). Furthermore, all symptoms except sleep 
disturbance had significant variability (random effects) at the initiation of CTX (p < 0.0001) and 
throughout the CTX trajectory (p < 0.05), which adds to the existing evidence of significant 
inter-individual variability in the symptom experience during CTX ( Berger, 1998, Berger and 
Higginbotham, 2000, Braud et al., 2003, Molassiotis and Chan, 2001, Schwartz, 1998 and 
Schwartz, 2000). However, this study was the first to demonstrate the variability in symptom 
trajectories across six cycles of CTX. 
 
Distress decreased significantly over time (p < 0.0001) which suggests that patients may 
experience some level of psychological adjustment over the course of CTX. While depression 
scores showed a negative slope over time, the rate was not significantly different from zero (p = 
0.49), unlike another study that reported a decrease in depression over time (Stommel et al., 
2004). It is important to note that not all of the patients had improvements in their psychological 
symptoms. The significant variability in both depression and distress suggest that inter-individual 
differences in patients’ experiences exist, as well as in their adjustments to these symptoms. For 
example, patients with lung cancer compared to those with colorectal cancer and lymphoma 
reported higher depression scores at the initiation of CTX which approached significance (p = 
0.051). Unlike other studies ( Kurtz et al., 2002 and Miaskowski, 2004), no gender differences in 
depression were found. A systematic review by Miaskowski (2004) revealed that some studies 
found a higher incidence of depression in older women and younger men. However, study 
findings were inconsistent and none were longitudinal (Miaskowski, 2004). 
 
Fatigue had the highest mean intensity of any symptom at the first cycle of CTX (3.9), and was 
consistent with previous reports (2.36–4.82) (Berger, 1998, Braud et al., 2003, Molassiotis and 
Chan, 2001 and Schwartz, 2000). However, in contrast to previous reports that suggested that the 
cumulative effects of CTX (Schwartz, 2000), high doses of CTX (Danaher et al., 2006) and 
chemoradiation (Reyes-Gibby et al., 2007 and Wang et al., 2006) resulted in cumulative 
increases in fatigue, fatigue severity in this study decreased over time. These differences may be 
attributed to the fact that other studies measured fatigue trajectories within CTX cycles for a 
maximum of three cycles while in this study, symptoms were measured at the beginning of each 
cycle and for a longer follow-up (i.e. six cycles of CTX). In this study, patients with more 
comorbidities experienced significantly more severe fatigue at baseline (p = 0.01). However, the 
linear slope was not significantly different from zero (flat line), which suggests that fatigue 
levels in patients with a higher number of comorbidities persisted throughout the CTX trajectory 
compared to other patients. A diagnosis of lung cancer predicted a significant increase in fatigue 
severity over time (p = 0.04) and is inconsistent with previous reports (Gift et al., 2004). 
 
Pain intensity decreased significantly over the six cycles of CTX (p < 0.01). However, 
heterogeneity in trajectories existed, as those who received concurrent radiation therapy reported 
significant increases in pain over the six cycles of CTX. This finding is consistent with a 
previous report (Wang et al., 2006) that found that the trajectory of pain increased over time in 
patients with nonsmall cell lung cancer undergoing chemoradiation. In addition, combined 
chemoradiation was shown to contribute to increased symptom burden ( Cooley et al., 2002 and 
Sarna et al., 2004), underscoring the importance of tailored symptom management. 
 
Comorbidities in this study were a significant predictor of fatigue at baseline and sleep 
disturbance over the six CTX cycles. While two cross-sectional studies reported a relationship 
between comorbidities and the number of overall symptoms (Gift et al., 2004) or the level of 
symptom distress (Sarna, 1993), no studies were found that reported on the influence that 
comorbidities can have on sleep disturbance or other symptom trajectories in patients undergoing 
CTX. In addition, the population is aging in many countries around the world, thereby reflecting 
an increase in cancer incidence. In relation to this change, older patients with increased numbers 
of comorbidities are receiving CTX (Balducci, 2003). A population-based study of 15,626 
patients with cancer, conducted between 1984 and 1992, revealed that 68.7% of cancer patients 
had comorbidities and that 32.6% had two or more comorbid conditions (Ogle et al., 2000). 
While age did not predict symptom severity in this study, the number of comorbidities did. The 
average number of comorbidities in this study was 2.5 with a range from zero to eight, consistent 
with previous findings [Ogle et al., 2000]. The influence that these comorbidities will have on 
CTX-related symptoms over time warrants further investigation. 
 
Because of several limitations, the findings from this study need to be interpreted with caution. 
First, the sample size was relatively small, and a large percentage of patients had advanced 
disease, likely due to the inclusion of lung cancer with only 16% of cancers diagnosed at early 
stage (American Cancer Society, 2008). Second, patients entered data into the PCM at each visit 
but not more than every two weeks, which resulted in a lack of consistent data on day one of 
each cycle. For example, some patients had week one and week three data of a four week cycle, 
but they did not have day one data of each cycle recorded. These omissions resulted in missing 
data along each of the time points. Also, because this study examined symptoms on day one of 
each cycle, the symptom experience between cycles (e.g. nadir) was not captured but rather, the 
data captured patients in recovery after each cycle. This potentially represents the least intensive 
symptoms experienced across the chemotherapy treatment trajectory. The growth curves may 
have been different if data were available at different times during the CTX cycle. 
 
Future opportunities for research are abundant. Studies that capture symptoms within each cycle 
of CTX and over an entire course of CTX are needed. Understanding finite details within and 
between cycles can provide a clearer picture of symptom trajectories during CTX. In addition, 
these findings present more questions about the management of symptoms in patients with 
multiple comorbidities which are critical in light of an aging population. For example, which 
comorbidities are most likely to contribute to more severe symptoms during CTX and throughout 
the cancer experience? Other essential studies will include the impact that symptom trajectories 
have on distal outcomes such as function. Furthermore, a need exists to conduct studies with 
more homogenous diagnoses and CTX regimens so that differences in functional forms for 
symptom trajectories can be identified. 
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